Bromokriptin i psykiatrisk praxis -en litteraturöversikt

References

• Barnes T. R E, Kidger T., Taylor P. J. On the use of dopamine agonists in tardive dyskinesia. Am J Psychiatry 1978; 135: 132–3
   PubMedGoogle Scholar
• Borenstein P., Soret C. H, Graille D. Contribution a ľétude des syndromes démentiels sous Taction de la bromocriptine. Sem Hop Paris 1981a; 57: 801–9
   PubMedGoogle Scholar
• Borenstein P., Soret C. H, Graille D. Intért de la bromocriptine dans les démences de la viellesse. Ann Med Psychol 1981b; 57: 326–34
   Google Scholar
• Borg V., Weinholdt T. Bromocriptine in the treatment of the alcohol-withdrawal syndrome. Acta Psychia-trica Scandinavica 1982; 65: 101–11
   PubMed Web of Science ®Google Scholar
• Borg V. Bromocriptine in the prevention of alcohol abuse. Acta psychiatr Scand 1983; 68: 100–10
   PubMed Web of Science ®Google Scholar
• Brook N. M., Cookson I. B. Bromocriptine-induced mania. (Letter to the editor) Br Med J 1978; 1: 790
   PubMedGoogle Scholar
• Bunney W. E., Brodie H. KH, Murphy D. L., Goodwin F. K. Studies of alpha-methyl-paratyrosine, L-dopa, and L-tryptophan in depression and mania. Am J Psychiatry 1971; 127: 48–57
   Google Scholar
• Calne D. B., Teychenne P. F., Claveria L. E., Eastman R., Greenacre J. K., Petrie A. Bromocriptine in parkinsonism. Br Med J 1974a; 4: 442–4
   PubMed Web of Science ®Google Scholar
• Calne D. B., Teychenne P. F., Leigh P. N., Bamji A. N., Greenacre J. K. Treatment of parkinsonism with bromocriptine. The Lancet (London) 1974b; 11: 1355–6
   Google Scholar
• Colonna L., Petit M., Lepine J. P. Intéret de la bromocriptine dans les schizophrénies dysthymiques. ľEn-céphale (Paris) 1978; 4: 115–17
   PubMedGoogle Scholar
• Colonna L., Petit M., Lepine J. P. Bromocriptine in affective disorders. J Affect Dis 1979; 1: 173–7
   PubMed Web of Science ®Google Scholar
• Corrodi H., Fuxe K. Hökfelt T, Lidbrink P, Ungerstedt U. Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. J Pharm Pharmacol 1973; 25: 409–12
   PubMed Web of Science ®Google Scholar
• Curzon G. CSF homovanillic acid: An index of dopaminergic activity. Adv Neurol 1975; 9: 349–57
   PubMedGoogle Scholar
• Delwaide P. J., Hurlet A. Bromocriptine and buccolin-guofacial dyskinesias in patients with senile dementia. Arch Neurol 1980; 37: 441–3
   PubMedGoogle Scholar
• Dorr C., Sathananthan K. Treatment of mania with bromocriptine (Letter to the editor). Br Med J 1976; 1: 1342–3
   PubMedGoogle Scholar
• Friis M. L, Grøn U., Larsen N. E., Pakkenberg H., Hvid-Berg E. F. Pharmacokinetics of bromocriptine during continuous oral treatment of Parkinson's disease. Eur J Clin Pharmacol 1979; 15: 275–80
   PubMed Web of Science ®Google Scholar
• Frye P. E., Pariser S. F., Kim M. H, O'Shaugnessy R. W. Bromocriptine associated with symptom exacerbation during neuroleptic treatment of schizoaffective schizophrenia. J Clin Psychiatry 1982; 43: 252–3
   PubMed Web of Science ®Google Scholar
• Gerner R. H., Post R. M., Bunney W. E. Dr Gerner and associates reply (Letter to the editor). Am J Psychiatry 1977; 134: 703
   PubMedGoogle Scholar
• Greenblatt M., Grosser G. H., Wechsler H. Differential response of hospitalized depressed patients to somatic therapy. Am J Psychiatry 1964; 116: 935–43
   Google Scholar
• Griffith R. W., Turkalj I., Braun P. Outcome of pregnancy in mothers given bromocriptine. Br J Clin Pharmacol 1978; 5: 227–31
   PubMed Web of Science ®Google Scholar
• Grimes J. D., Hassan M. N. Bromocriptine in the long-term management of advanced Parkinson's disease. Can J Neurol Sci 1983; 10: 86–90
   PubMed Web of Science ®Google Scholar
• Horrobin D. F., Mtabaji J. P., Karmali R. A., Manku M. S., Nassar B. A. Prolactin and mental illness. Postgrad Med J (Suppl 3) 1976; 52: 78–85
   Google Scholar
• Hökfelt T., Fuxe K. On the morphology and the neuroendocrine role of the hypothalamic catecholamine neurons. Brain endocrine interaction, K. M. Knigge, D. E. Scott, A. Weindle. S Karger, Basel 1972; 181–223
   Google Scholar
• Jansen E. N H. Bromocriptine in levodopa response-losing parkinsonism. Eur Neurol 1978; 17: 92–9
   PubMedGoogle Scholar
• Jeste D. V., Cutler N. R., Kaufmann C. A. Low-dose apomorphine and bromocriptine in neuroleptic -induced movement disorders. Biol Psychiatry 1983; 18: 1085–91
   PubMedGoogle Scholar
• Johnson A. M., Loew D. M., Vigouret J. M. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine. (+)-amphetamine and L-dopa. Br J Pharmacol 1976; 56: 59–68
   PubMed Web of Science ®Google Scholar
• Johnson J. M. Treated mania exacerbated by bromocriptine. Am J Psychiatry 1981; 138: 980–2
   PubMed Web of Science ®Google Scholar
• Kartzinel R., Perlow M. D., Carter A. C., Chase T. N., Calne D. B., Shoulson I. Metabolic studies with bromocriptine in patients with idiopathic parkinsonism and Huntington's chorea. Trans Am Neurol Assoc 1976; 101: 53–6
   PubMedGoogle Scholar
• Kobberling J., Jüppner H., Volkmann B., Unger K., Schwinn G., Dirks H. Suppression of growth hormone by bromocryptine (CB 154) in acromegalics, lack of suppression in normals. Acta Endrocri-nologica (Suppl) 1975; 193: 93
   Google Scholar
• Lamberts S., Birkenh W J, Uger J. C. Effect of bromocriptine in pituitary-dependent Cushing's syndrome. J Endocrinol 1976; 70: 315–16
   PubMed Web of Science ®Google Scholar
• Lees A. J. Bromocriptine. Br J Hosp Med 1977; 18: 336–8
   PubMedGoogle Scholar
• Liuzzi A., Chiodini P. G., Botalla L., Cremascoli G., Miiller E. E., Silvestrini F. Decreased plasma growth hormone (GH) levels in acromegalics following CB 154 (2-Br-α-ergocryptine) administration. J Clin Endocrinol Metab 1974; 38: 910–12
   PubMed Web of Science ®Google Scholar
• Mihovilovic M., Bohaček N. Bromocriptin in depressive states. Abstract XI CINP Congress, Wien, 1978; 211
   Google Scholar
• Modigh K. Long-term effects of electroconvulsive shock therapy on synthesis turnover and uptake of brain monoamines. Psychopharmacology 1976; 49: 179–85
   PubMed Web of Science ®Google Scholar
• Morris J. B., Beck A. T. The efficacy of antidepressant drugs. A review of research (1958 to 1972). Arch Gen Psychiatry 1974; 30: 667–74
   PubMed Web of Science ®Google Scholar
• Murphy D. L., Brodie H. KH, Goodwin F. K., Bunney W. E. Regular induction of hypomania by L-dopa in bipolar manic-depressive patients. Nature (London) 1971; 229: 135–6
   PubMed Web of Science ®Google Scholar
• Nordin C., Siwers B., Bertilsson L. Bromocriptine treatment of depressive disorders. Clinical and biochemical effects. Acta Psychiatr Scand 1981; 64: 25–33
   PubMed Web of Science ®Google Scholar
• Ose E. Depresjoner behandlet med bromocriptin (Parlodel) og imipramin i et kontrollert klinisk forsok (dobbelt-blind-forsok). Forelopig meddelelse. Nord Psykiatr Tids 1980; 34: 578–84
   Google Scholar
• Parkes D. Bromocriptine. New Engl J Med 1979; 301: 873–8
   PubMed Web of Science ®Google Scholar
• Pasteels J. L., Danguy A., Frérotte M, Ectors F. Inhibition de la sécrétion de prolactine par ľergocornine et la 2-Br-α-ergocryptine: action directe sur 1'hypophyse en culture. Ann ďEndocrinol 1971; 32: 188–92
   PubMedGoogle Scholar
• Pöldinger W. Therapy of extrapyramidal side effects, with particular reference to persistent dyskinesia and lithium tremor. Int Pharmacopsychiatry 1978; 13: 230–3
   PubMedGoogle Scholar
• Ringwald E. Behandlung von neuroleptischen Spathy-perkinesien mit Antiparkinsonika. Pharmacopsyc-hiatria 1978; 11: 294–8
   Google Scholar
• Ringwald E., Lustig A., Moscovici M., Spiegel R., Vamos E. Applikation von Bromocriptin in hohen Einzel-dosen bei schizophrenen Patienten mit erhohten Prolaktinwerten und neuroleptisch bedingten extra- pyramidalen Störungen. Pharmacopsychiatria 1980; 13: 318–24
   Google Scholar
• Roccatagliata G., Albano C., Cocito L., Abbruzzese G., Gandolfo C., Primavera A. Terapia delle sindromi depressive con bromocriptina. Simposio della Società Italiana de Neuropsicofarmacologia, Capri Giugno, 1–2, 1976, 239–44
   Google Scholar
• Saran B. M., Acharya S. Bromocriptine in treating mania. (Letter to the editor). Am J Psychiatry 1977; 134: 702–3
   PubMedGoogle Scholar
• Schubert H., Fleischhacker W. W., Demel I. Bromocriptin bei organischen Depressionen. Pharmacopsychiatria 1982; 15: 103–6
   PubMedGoogle Scholar
• Serby M., Angrist B., Lieberman A. Mental disturbances during bromocriptine and lergotrile treatment of Parkinson's disease. Am J Psychiatry 1978; 135: 1227–9
   PubMed Web of Science ®Google Scholar
• Serby M., Angrist B., Lieberman A. Psychiatric effects of bromocriptine and lergotrile in Parkinsonian patients. Adv Biochem Psychopharmacol 1980; 23: 287–92
   PubMedGoogle Scholar
• Smith A. H W, Chambers C., Naylor G. J. Bromocriptine in mania - a placebo controlled double-blind trial. Br Med J 1980; 280: 86
   PubMedGoogle Scholar
• Smith R. C., Tamminga C., Davis J. M. Dr Smith and associates reply (Letter to the editor). Am J Psychiatry 1978; 135: 133
   PubMedGoogle Scholar
• Snider S. R., Hutt C., Stein B., Prasad A. L N, Fahn S. Correlation of behavioural inhibition or excitation produced by bromocriptine with changes in brain catecholamine turnover. J Pharm Pharmacol 1976; 28: 563–6
   PubMed Web of Science ®Google Scholar
• Tamminga C. A., Chase T. N. Bromocriptine and CF 25–297 in the treatment of tardive dyskinesia. Arch Neurol 1980; 37: 204–5
   PubMedGoogle Scholar
• Theohar C., Fischer-Cornelssen K., Åkesson H. O., Ansari J., Gerlach J., Harper P., Öhman R., Ose E., Stegink A. J. Bromocriptine as antidepressant: double-blind comparative study with imipramine in psychogenic and endogenous depression. Curr Ther Res 1981; 30: 830–42
   Web of Science ®Google Scholar
• Thorner M. O, McNeilly A. S., Hagan C., Besser G. M. Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. Br Med J 1974; 2: 419–22
   PubMed Web of Science ®Google Scholar
• Tolis G., Pinter E. J., Friesen H. Metabolic and endocrine actions of 2 bromo - ergocryptine (CB 154). Int J Clin Pharmacol Ther Toxicol 1974; 10: 151
   Google Scholar
• Thrabucchi M., Andreoli V. M., Frattola L., Spano P. F. Pre- and postsynaptic action of bromocriptine: its pharmacological effects in schizophrenia and neurological diseases. Adv Biochem Psychopharmacol 1977; 16: 661–5
   PubMedGoogle Scholar
• Vardi J., Flechter S., Oberman Z., Segal R., Shogan G., Haker O. Plasma dopamine β hydroxylase activity in chronic schizophrenic patients tested with single dose of 2-bromo-alpha-ergocriptine (Parlodel) ľ. Encéphale (Paris) 1981; 7: 95–103
   PubMedGoogle Scholar
• Vlissides D. N., Gill D., Castelow J. Bromocriptine-indu-ced mania? (Letter to the editor). Br Med J 1978; 1: 510
   PubMedGoogle Scholar
• Waehrens J., Gerlach J. Bromocriptine and imipramine Shoulson I, Steinsand O. Bromocriptine inhibits in endogenous depression. J Affect Dis 1981; 3: 202, 193- norepinephrine release. Clin Pharmacol Ther 1979
   Google Scholar
• Ziegler M. G., Lake C. R., Williams A. C, Teychenne P. F, Shoulson I., Steinsand O. Bromocriptine inhibits norepinephrine release. Clin Pharmacol Ther 1979; 25: 137–42
   PubMed Web of Science ®Google Scholar